Currents (Tame Impala album)

Currents is the third studio album by Australian psychedelic rock act Tame Impala, released on 17 July 2015 on Interscope Records. Like the group's previous two albums, Currents was written, recorded, performed, and produced by primary member Kevin Parker. For the first time, Parker also mixed the music. It was also the first time that Parker recorded all instruments by himself; the album featured no other collaborations.

After releasing the group's previous record, Lonerism (2012), Parker began work on Currents, largely recording at his home studio in Fremantle. He engrossed himself with writing and recording, and owing to his reputation as a musical auteur, labored over the details of each song, ultimately causing the release date to be delayed by two months. In contrast to the psychedelic rock sound of the project's prior work, Currents marks a shift to more dance-oriented music, with more emphasis placed on synthesizers than guitars. Parker was inspired to seek a change out of desire to hear Tame Impala's music played in dance clubs and a more communal setting. Thematically, the record is about the process of personal transformation, which many critics interpreted to be the result of a romantic break-up. The album's cover art depicting vortex shedding is a visualization of these themes.

Currents (Eisley album)

Currents is the fourth full-length album by the band Eisley. It was released on May 28, 2013, on Equal Vision Records. The title-track song "Currents," is the first official single from the album, and was publicly released on April 23, 2013. On April 16, 2013, Eisley released an online stream of the song "Drink The Water," hosted by Nylon Magazine. The streaming of this song marked the first full length song to be heard from Currents.

The album charted at number 66 on the Billboard 200, making it the group's highest charting album to date.

Production (May–October, 2012)

The group began production of their fourth studio album on May 5, 2012 in their studio constructed in their hometown of Tyler, TX. The studio, built by members Weston Dupree and Garron DuPree, alongside their audio engineer Mark Schwartzkopf. The studio itself was built to be attached to the house of singer Sherri DuPree-Bemis, and Say Anything frontman Max Bemis. Upon completion of the studio in late April 2012, the group began the pre-production and tracking of the album in early May, 2012.

Latest News for: uric currents

Uric acid is a ... In human liver cells, Acquist's clinical lead (ACQT1127) has sharply reduced uric acid and triglycerides, and has renormalized aberrant activity of enzymes targeted by monofunctional drugs currently sponsored in NASH clinical trials by other companies....

The company believes that the results thus far help to support the narrative that the drug has the potential to change the paradigm for treating patients with chronic severe gout by providing a better and more sustained uric acid control, less flare ups, and less frequent dosing relative to the current standard of care....

This reduced rate of gout flares appears to be substantially lower than the incidence of gout flares reported in clinical trials involving the current FDA-approved uricase and also other uric acid lowering therapies ... versus the current approved uricase which is diluted....

Those data indicates that our product profile may provide better and more sustained serum uric acid level control over time, fewer gout flares and convenient monthly dosing compared with recent data reported for the current FDA-approved uric acid therapy....

This is a product candidate consisting of pegsiticase, a uricase enzyme that has been shown to significantly lower uric acid levels in the blood, combined with SVP-Rapamycin to mitigate immunogenicity that normally occurs from the dosing of the uricase enzyme ...There iscurrently only one FDA-approved therapy for severe gout patients....

In these studies, Arhalofenate consistently demonstrated the ability to reduce gout flares as well as reduce serum uric acid ... We believe that the potential for Arhalofenate to prevent or reduce flares while also lowering serum uric acid will significantly differentiate it from currently available therapies for gout....

This dual mechanism of action with a single agent is potentially valuable because it would address the two biggest unmet need the almost 2 million gout patients that are inadequately treated with currently available therapies for the additional uric acid lowering to be able to ......